THE NECESSITY OF INTRODUCTION THE DRUG INSURANCE SYSTEM IN ARMENIA
Abstract
The increase in the cost of the medicinal component of the treatment, the spread of chronic diseases, and the maintenance of socio-economic inequality in access to health services require the provision of adequate access to medicines. These issues create prerequisites for the improvement of the state health policy and, first, the drug supply system, which is an integral part of the treatment process. The financing of healthcare in Armenia is mainly formed from budget allocations and out of pocket expenditures of the population. Reducing the financial burden on the state and ensuring the rational use of drugs contributes to improving the health of the population. The implementation of a drug insurance scheme, which partially or fully cover the cost of drugs in RA, is one of the solutions for resolving the issue of access to medicines. This article studies the problems of financing healthcare system in Armenia and highlights the need of introduction a drug insurance system in Armenia
References
Berkeley, B. (2017) Relationship between Health Provider Status and Social Interaction. Open Access Library Journal, 4, 1-7. DOI: 10.4236/oalib.1103708
Mateu C, Guerlain A. (2019) Global Legal Insights - Pricing & Reimbursement 2019, Second Edition, pp. 65-83. Retrieved from https://www.acc.com/sites/default/files/resources/upload/GLI_P%26R19_E-edition_.pdf
Current health expenditure (% of GDP). World Health Organization Global Health Expenditure database (apps.who.int/nha/database). The data was retrieved on January 30, 2022.
Finance Statistics of Armenia 2015-2020. Retrieved from https://www.armstat.am/file/article/finansner_2021_1.pdf
Global expenditure on health: public spending on the rise? Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.
Gottret, P., and G. Schieber. 2006. Health Financing Revisited: A Practitioner’s Guide. Washington, D.C.: World Bank, pp.340. Retrieved from http://siteresources.worldbank.org/INTHSD/Resources/topics/Health-Financing/HFRFull.pdf
Hayrapetyan N. (2018), State regulation of the health sector and contemporary problems of management in the RA, pp.121. Retrieved from http://dspace.paara.am/xmlui/handle/123456789/108
Tracking universal health coverage, Global Monitoring Report on Universal Health Coverage 2021 (as of 12th December 2021), pp. 103. Retrieved from https://cdn.who.int/media/docs/default-source/world-health-data-platform/events/tracking-universal-health-coverage-2021-global-monitoring-report_uhc-day.pdf?sfvrsn=fd5c65c6_5&download=true
Nguyen T, Rosemary Knight, Roughead E, Brooks G. and Mant A. (2013) Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries, Health Policy and Planning 2015;30:267–280 doi:10.1093/heapol/czt105, Published by Oxford University Press in association with The London School of Hygiene and Tropical Medicine, pp. 267-280. Retrieved from https://www.jstor.org/stable/48508608
Ozieranski P. & King L. (2017) Governing drug reimbursement policy in Poland: The role of the state, civil society, and the private sector, Theor Soc (2017) 46:577–610 https://doi.org/10.1007/s11186-017-9300-8, pp. 577-610. Retrieved from https://link.springer.com/content/pdf/10.1007/s11186-017-9300-8.pdf
Ngorsuraches S, Meng W., Kim B., Kulsomboon V. (2011) Drug Reimbursement Decision-Making in Thailand, China, and South Korea, Volume 15, Issue 1, Supplement, January–February 2012, p. 120-125, https://doi.org/10.1016/j.jval.2011.11.002Get rights and content, Under an Elsevier user license. Retrieved from https://www.sciencedirect.com/science/article/pii/S109830151103539X
S. Aghajanyan (2020). Will Armenia’s Healthcare System Hold the Impact of a Protracted Pandemic?, Amberd Bulletin 2020/2, pp. 32-37, Retrieved from https://artsakhlib.am/2020/06/22/%d5%af%d5%a4%d5%ab%d5%b4%d5%a1%d5%b6%d5%a1%d5%9e-%d5%a1%d6%80%d5%a4%d5%b5%d5%b8%d6%84-%d5%b0%d5%b0-%d5%a1%d5%bc%d5%b8%d5%b2%d5%bb%d5%a1%d5%ba%d5%a1%d5%b0%d5%a1%d5%af%d5%a1%d5%b6-%d5%b0%d5%a1%d5%b4/
World Bank Data, Retrieved from https://data.worldbank.org/indicator/SH.XPD.CHEX.GD.ZS?fbclid=IwAR1Ti0CNhRMBi3Y6hXBky4EO_Aw-hOSiv75BNYtDGlFKjVstb-itYqdwOTw&locations=AM
World Health Organization (2018) Medicines Reimbursement Policies in Europe, pp. 200, https://apps.who.int/iris/bitstream/handle/10665/342220/9789289053365-eng.pdf?sequence=1&isAllowed=y
Варианты политики в сфере возмещения стоимости лекарственных средств в Европе (2018) https://apps.who.int/iris/bitstream/handle/10665/350653/9789289056106-rus.pdf p. 31
Попович Л. (2019) Лекарственное страхование – выбор пути, с. 6-16. DOI: https://doi.org/10.21518/1561–5936–2019–04-6-16. Retrieved from https://cyberleninka.ru/article/n/lekarstvennoe-strahovanie-vybor-puti/viewer
Глембоцкая Г., Богатырев С. (2009) Страхование лекарственного обеспечения как средство повышения качества медицинской помощи, ВЕСТНИК ВГУ, серия: химия. биология. фармация, 2009, № 1, ст. 107-112, Retrieved from http://www.vestnik.vsu.ru/pdf/chembio/2009/01/2009-01-20.pdf
Retrieved from https://nih.am/assets/pdf/atvk/af1c36a476d2ad4a41609a5fde974319.pdf
Views:
244
Downloads:
244
Copyright (c) 2022 Susanna Aghajanyan, Lusine Karapetyan, Arsen Petrosyan, Tatevik Vardanyan, Tigran Mikayelyan, Anna Ayvazyan, Gagik Hakobyan
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
